Showing results (31-40 of 43) with videos related to

Sort By:
Pageof 5
AIDS Research and Therapy|March 22, 2024
Efficacy and safety of switching to dolutegravir/lamivudine in virologically suppressed people with HIV-1 aged ≥ 50 years: week 48 pooled results from the TANGO and SALSA studiesSharon Walmsley, Don E Smith, Miguel Górgolas, et al.
Frontiers in Medicine|May 29, 2024
Multiple treatment interruptions and protecting HIV-specific CD4 T cells enable durable CD8 T cell response and viral controlAnshika Jain, Gaspar E Canepa, Mei-Ling Liou, et al.
Infectious Diseases and Therapy|September 26, 2023
Week 240 Efficacy and Safety of Fostemsavir Plus Optimized Background Therapy in Heavily Treatment-Experienced Adults with HIV-1Judith A Aberg, Bronagh Shepherd, Marcia Wang, et al.
Open Forum Infectious Diseases|January 13, 2022
Safety and Efficacy of Tocilizumab 4 or 8 mg/kg in Hospitalized Patients With Moderate to Severe Coronavirus Disease 2019 Pneumonia: A Randomized Clinical TrialPrincy N Kumar, Jules Hernández-Sánchez, Sandra Nagel, et al.
AIDS (London, England)|May 4, 2021
Long-term efficacy and safety of fostemsavir among subgroups of heavily treatment-experienced adults with HIV-1Peter Ackerman, Melanie Thompson, Jean-Michel Molina, et al.
The Lancet. HIV|October 31, 2020
Safety and efficacy of the HIV-1 attachment inhibitor prodrug fostemsavir in heavily treatment-experienced individuals: week 96 results of the phase 3 BRIGHTE studyMax Lataillade, Jacob P Lalezari, Michael Kozal, et al.
The Lancet. Infectious Diseases|May 14, 2013
Efficacy and safety of raltegravir for treatment of HIV for 5 years in the BENCHMRK studies: final results of two randomised, placebo-controlled trialsJoseph J Eron, David A Cooper, Roy T Steigbigel, et al.
Lancet (London, England)|January 16, 2010
Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trialsJoseph J Eron, Benjamin Young, David A Cooper, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 21, 2010
Long-term efficacy and safety of Raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 Phase III trialsRoy T Steigbigel, David A Cooper, Hedy Teppler, et al.
Annals of Neurology|January 5, 2023
Monkeypox-Associated Central Nervous System Disease: A Case Series and ReviewKelli M Money, T Allen Barnett, Samuel Rapaka, et al.
Pageof 5